An indirect comparison between ACT and GEMINI trials is, however, improper since the two studies had a different design and enrolled a different IBD population, with 48% of subjects previously exposed to anti-TNFα in the GEMINI trial. The gene discussed is TNF; the disease is inflammatory bowel disease.